Stx-mediated disease and immunomodulatory effectors of enterohemorrhagic E.coli

描述（由申请方提供）：肠出血性大肠杆菌（EHEC）O157：H7是一种可导致危及生命疾病的重要病原体。肠出血性大肠杆菌感染的抗生素治疗与更严重的全身性疾病有关。因此，需要更深入地了解这种病原体的毒力特性，以产生新的治疗策略。这种病原体的效力源于两种主要毒力组分的组合活性：Stx毒素和复杂的III型分泌系统（TTSS），包括注射到哺乳动物细胞中的相关效应蛋白。虽然这些成分中的每一个都被广泛研究，但对这两种主要毒力机制如何相互作用和协同作用知之甚少。例如，Stx的组织破坏作用被宿主先天免疫反应大大增强，Rosenshine博士的实验室（以及其他实验室）已经表明，一组III型分泌的“免疫调节”效应蛋白下调宿主的炎症反应。解决免疫调节效应物影响的一个主要障碍是缺乏在宿主TTSS依赖性定殖的背景下重现Stx活性的模型系统。申请人最近开发的两个模型允许进行这种研究。一种是使用一种经过基因工程改造的产生Stx的C.啮齿动物，一种编码TTSS和效应子集合的鼠病原体，与EHEC非常相似。这个工程C。啮齿动物引起的鼠疾病，像人类肠出血性大肠杆菌感染一样，以肠道损伤、肾功能障碍、进行性体重减轻和死亡为特征。第二种模型涉及EHEC感染SCID小鼠中的人肠异种移植物，这是一种模拟人感染的模型，特别是关于EHEC对结肠组织的记录向性。 深入了解减少或加剧严重Stx介导的疾病的因素可能会导致新的和必要的战略，以防止EHEC感染的最致命的后果。作为实现这一长期目标的第一步，我们研究了一组重要的效应蛋白，这些效应蛋白已被证明在体外调节宿主细胞的炎症反应。为了测试体外鉴定的这些效应物的免疫调节活性是否准确地反映体内抗炎作用，以及这些效应物蛋白是否影响Stx的递送、传播和引起全身性疾病的能力，我们将追求以下具体目标： 1. CR（？）stx2dact）和免疫调节效应物产生缺陷的EHEC菌株。 2.表征上述一套CR（？stx2dact）菌株定殖小鼠并引起局部和全身Stx介导的损伤。 3.使用人肠异种移植物模型表征上述EHEC菌株组引起局部和全身Stx介导的损伤的能力。

DESCRIPTION (provided by applicant): Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is an important pathogen that causes life-threatening disease. Antibiotic treatment of EHEC infection is associated with more severe systemic disease. Thus, a deeper understanding of the virulence properties of this pathogen is needed to generate new therapeutic strategies. The potency of this pathogen stems from the combined activity of two major virulence components: Stx toxin and a complex type III secretion system (TTSS), including the associated effector proteins that are injected into mammalian cells. While each of these components was studied extensively, little is known on how these two major virulence mechanisms might interact and synergize. For example, the tissue damaging action of Stx is greatly potentiated by the host innate immune response, and Dr. Rosenshine's laboratory (as well as others) has shown that a group of type III-secreted "immunomodulatory" effector proteins down-regulate the inflammatory response of the host. A major obstacle in addressing the influence of immunomodulatory effectors has been the lack of a model system that recapitulates Stx activity in the context of TTSS-dependent colonization of the host. Two models recently developed by the applicants allow such studies. One employs a genetically engineered Stx-producing strain of C. rodentium, a murine pathogen that encodes a TTSS and a collection of effectors very similar to those of EHEC. This engineered C. rodentium induces a murine disease that, like human EHEC infection, features intestinal damage, renal dysfunction, progressive weight loss and death. A second model involves EHEC infection of human intestinal xenografts in SCID mice, a model that mimics human infection, particularly with respect to the documented tropism of EHEC for colonic tissue. Insights into factors that diminish or exacerbate serious Stx-mediated disease may lead to new and needed strategies to prevent the most lethal consequences of EHEC infection. As a first step towards achieving this long-term goal, we investigate an important group of effector proteins that have been shown to modulate the inflammatory response of host cells in vitro. To test whether the immunomodulatory activities of these effectors identified in vitro accurately reflect anti-inflammatory effects in vivo, and whether these effector proteins influence the delivery, dissemination and capacity of Stx to cause systemic disease, we will pursue the following specific aims: 1. Construction and in vitro characterization of CR (?stx2dact) and EHEC strains defective for production of the immunomodulatory effectors. 2. Characterization of the ability of the above set of CR (?stx2dact) strains to colonize mice and cause local and systemic Stx-mediated damage. 3. Characterization of the ability of the above set of EHEC strains to cause local and systemic Stx-mediated damage using the human intestinal xenograft model.